Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Natalie L David"'
Autor:
Bokai Zhu, Silvia Liu, Natalie L. David, William Dion, Nandini K Doshi, Lauren B. Siegel, Tânia Amorim, Rosemary E. Andrews, GV Naveen Kumar, Saad Irfan, Tristan Pesaresi, Ankit X. Sharma, Michelle Sun, Pouneh K. Fazeli, Matthew L. Steinhauser
Publikováno v:
bioRxiv
While circadian rhythms are entrained to the once daily light-dark cycle of the sun, many marine organisms exhibit ~12h ultradian rhythms corresponding to the twice daily movement of the tides. Although human ancestors emerged from circatidal environ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae0fe27a922a365ff5b17338e53e8acf
https://doi.org/10.1101/2023.05.02.539021
https://doi.org/10.1101/2023.05.02.539021
Autor:
null Sabashini K. Ramchand, null Natalie L. David, null Hang Lee, null Michael Bruce, null Mary L. Bouxsein, null Joy N. Tsai, null Benjamin Z. Leder
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24395ad42dc45df36a42cc01a7b79054
https://doi.org/10.1002/jbmr.4737/v2/response1
https://doi.org/10.1002/jbmr.4737/v2/response1
Autor:
Benjamin Z. Leder, Sabashini K Ramchand, Joy N. Tsai, Natalie L David, Hang Lee, Richard Eastell
Publikováno v:
Journal of Bone and Mineral Research. 36:921-930
Combined teriparatide and denosumab rapidly and substantially increases bone mineral density (BMD) at all anatomic sites. Discontinuation of denosumab however, results in high-turnover bone loss and increased fracture risk. The optimal way to prevent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b65b75a6b098b30c551c36162dee2e9a
https://doi.org/10.1002/jbmr.4259
https://doi.org/10.1002/jbmr.4259
Autor:
Sabashini K Ramchand, Joy N. Tsai, Benjamin Z. Leder, Hang Lee, Michael Bruce, Natalie L David, Mary L. Bouxsein
Publikováno v:
Journal of Bone and Mineral Research. 36:41-51
In postmenopausal women at high risk of fracture, we previously reported that combined denosumab and high-dose (HD; 40 μg) teriparatide increased spine and hip bone mineral density (BMD) more than combination with standard-dose teriparatide (SD; 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4f5308c93d7d55b7ae69c6cb8ed7726
https://doi.org/10.1002/jbmr.4161
https://doi.org/10.1002/jbmr.4161
Publikováno v:
The Lancet Diabetes & Endocrinology. 7:767-775
SUMMARY: BACKGROUND: In the Denosumab and Teriparatide Administration (DATA) study, we showed that denosumab fully inhibits teriparatide-induced bone resorption while allowing for continued teriparatide-induced bone formation, resulting in larger inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b85b3d1f1400da4bd7464e064313c47
https://doi.org/10.1016/s2213-8587(19)30255-4
https://doi.org/10.1016/s2213-8587(19)30255-4
Publikováno v:
J Clin Endocrinol Metab
Context In the Denosumab and High-Dose Teriparatide Administration (DATA-HD) study, we reported that 15 months of combined high-dose (HD) teriparatide and denosumab increased mean areal bone mineral density (aBMD) at the hip and spine more than combi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c8232e9302eced2431f96217592c841
https://pubmed.ncbi.nlm.nih.gov/31674641
https://pubmed.ncbi.nlm.nih.gov/31674641